These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38648082)

  • 1. Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer.
    Archer M; Begemann D; Gonzalez-Kozlova E; Nepali PR; Labanca E; Shepherd P; Dogra N; Navone N; Kyprianou N
    Mol Cancer Res; 2024 Aug; 22(8):730-745. PubMed ID: 38648082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer.
    Martin SK; Pu H; Penticuff JC; Cao Z; Horbinski C; Kyprianou N
    Cancer Res; 2016 Feb; 76(4):912-26. PubMed ID: 26645563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
    Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.
    Kahn B; Collazo J; Kyprianou N
    Int J Biol Sci; 2014; 10(6):588-95. PubMed ID: 24948871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
    van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
    Mout L; van Royen ME; de Ridder C; Stuurman D; van de Geer WS; Marques R; Buck SAJ; French PJ; van de Werken HJG; Mathijssen RHJ; de Wit R; Lolkema MP; van Weerden WM
    EBioMedicine; 2021 Nov; 73():103681. PubMed ID: 34749299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
    Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
    Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F
    Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
    Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
    Sennoune SR; Nelius T; Jarvis C; Pruitt K; Kottapalli KR; Filleur S
    PLoS One; 2020; 15(6):e0234078. PubMed ID: 32484838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fisetin Enhances Chemotherapeutic Effect of Cabazitaxel against Human Prostate Cancer Cells.
    Mukhtar E; Adhami VM; Siddiqui IA; Verma AK; Mukhtar H
    Mol Cancer Ther; 2016 Dec; 15(12):2863-2874. PubMed ID: 27765854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YM155 Reverses Cabazitaxel Resistance in Castration-resistant Prostate Cancer by Reducing Survivin Expression.
    Miyao T; Koike H; Sekine Y; Ohtsu A; Oka D; Suzuki K
    Anticancer Res; 2020 Sep; 40(9):5091-5095. PubMed ID: 32878797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
    de Morrée E; van Soest R; Aghai A; de Ridder C; de Bruijn P; Ghobadi Moghaddam-Helmantel I; Burger H; Mathijssen R; Wiemer E; de Wit R; van Weerden W
    Prostate; 2016 Jul; 76(10):927-36. PubMed ID: 26997363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model.
    Mout L; de Wit R; Stuurman D; Verhoef E; Mathijssen R; de Ridder C; Lolkema M; van Weerden W
    EBioMedicine; 2018 Jan; 27():182-186. PubMed ID: 29276148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
    Colditz J; Rupf B; Maiwald C; Baniahmad A
    Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer: cabazitaxel--the taxane of choice in the new mCRPC landscape?
    Oudard S; Angelergues A
    Nat Rev Urol; 2014 Jul; 11(7):370-2. PubMed ID: 24960604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
    Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
    Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.